[The genetic factors of non-response to anti-vascular endothelial growth factor therapy]

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Anti-vascular endothelial growth factor (VEGF) treatments are crucial for various eye conditions.
• Treatment efficacy is variable, with patients classified as optimal responders, poor responders, or non-responders.
• The exact reasons for poor or non-response to anti-VEGF therapy are not fully understood.

Purpose of the Study:

• To explore the genetic factors contributing to variable responses to anti-VEGF treatment.
• To identify potential genetic markers for predicting treatment outcomes.
• To facilitate personalized treatment strategies and improve therapeutic efficacy.

Main Methods:

• Review of existing literature on genetic polymorphisms associated with anti-VEGF treatment response.
• Analysis of studies focusing on genes such as VEGF-A, VEGFR-2, CFH, ARMS2, HTRA1, and IL-8.
• Discussion of the implications of genomic variations on treatment outcomes.

Main Results:

• Non-response to anti-VEGF therapy can be influenced by multiple factors including age, baseline vision, disease progression, lesion characteristics, and genetic variations.
• Current research primarily focuses on specific genes (e.g., VEGF, CFH, ARMS2) but a comprehensive understanding is lacking.
• Genomic polymorphism is a significant area for further investigation.

Conclusions:

• Understanding the genetic basis of non-response is critical for optimizing anti-VEGF therapy.
• Further research into genetic factors can lead to individualized treatment plans.
• Predicting patient response based on genetic profiles holds promise for improving ophthalmic care.